NASDAQ: CRVOCervomed Inc Stock
$10.80+1.64 (+17.9%)
Updated Nov 29, 2024
CRVO Price
$10.80
Fair Value Price
N/A
Market Cap
$89.14M
52 Week Low
$5.85
52 Week High
$26.38
P/E
-4.95x
P/B
1.95x
P/S
12.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.07M
Earnings
-$11.95M
Gross Margin
100%
Operating Margin
-118.68%
Profit Margin
-118.7%
Debt to Equity
0.07
Operating Cash Flow
-$11M
Beta
0.55
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRVO Overview
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRVO's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Value
D
Growth
C
Momentum
D
Sentiment
F
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRVO
Ranked#320 of 340
Ranked#320 of 340
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.61 | A | |
| $7.72 | A | |
| $57.68 | A |
Be the first to know about important CRVO news, forecast changes, insider trades & much more!
CRVO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRVO is good value based on its book value relative to its share price (1.95x), compared to the US Biotechnology industry average (5.61x)
P/B vs Industry Valuation
CRVO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRVO due diligence checks available for Premium users.
Valuation
CRVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.95x
Industry
-107.59x
Market
27.74x
CRVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.95x
Industry
5.61x
CRVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRVO's financial health
Profit margin
Revenue
$1.9M
Net Income
-$4.8M
Profit Margin
-245.1%
CRVO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRVO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$48.9M
Liabilities
$3.2M
Debt to equity
0.07
CRVO's short-term assets ($48.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRVO's short-term assets ($48.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.9M
Investing
$2.6M
Financing
-$13.3k
CRVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRVO vs Biotech Stocks
Cervomed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.